HebeCell

HebeCell is a private, pre-clinical stage biotech developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer using its proprietary ProtoNK™ manufacturing platform. Founded by seasoned stem cell scientists, the company aims to overcome limitations of autologous cell therapies by creating a scalable, cost-effective source of potent NK cells. In addition to its internal therapeutic pipeline, HebeCell offers cryopreserved cells, custom cell production, and contract manufacturing services to generate early revenue and support platform validation.

Patented ProtoNK™ platform for scalable, bioreactor-based production of allogeneic natural killer (NK) cells from pluripotent stem cells (PSCs), aiming to mimic natural hematopoiesis to yield potent, non-exhausted cells.

HebeCell competes in the rapidly evolving allogeneic NK cell therapy arena against well-funded players like Fate Therapeutics, Century Therapeutics, and Nkarta, which also utilize iPSC or cell line engineering approaches. Differentiation hinges on the unique bioreactor-based manufacturing process and the resulting cell phenotype.